# EDGAR Filing Document

**Accession Number:** 0001982444
**File Stem:** 0001104659-26-025589
**Filing Date:** 2026-3
**Character Count:** 35362
**Document Hash:** 0620774d91bc45858a81d43c0c28e32d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-025589.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001104659-26-025589

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Baird Medical Investment Holdings Ltd
- **CENTRAL INDEX KEY:** 0001982444
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294172
- **FILM NUMBER:** 26737368

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 18/F, OVEST
- **STREET 2:** 77 WING LOK STREET
- **CITY:** SHEUNG WAN
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 86 159 1316 5120

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 18/F, OVEST
- **STREET 2:** 77 WING LOK STREET
- **CITY:** SHEUNG WAN
- **PROVINCE COUNTRY:** K3

**As filed with the Securities and Exchange Commission on March 10, 2026**

**Registration No.**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Baird Medical Investment Holdings Limited**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Cayman Islands** | **Not Applicable** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**Room 202, 2/F, Baide Building, Building 11, No.15**

**Rongtong Street, Yuexiu District, Guangzhou, Peoples Republic of China**

**(86) 20 8218-5926**

(Address of Principal Executive Offices)

**2024 Equity Incentive Plan**

(Full title of the plan)

**Puglisi & Associates**

**850 Library Avenue, Suite 204**

**Newark, DE 19711**

(Name and address of agent for service)

**(302) 738-6680**

(Telephone number, including area code, of agent for service)

***Copies to:***

**Dan Ouyang, Esq.**

**K. Ronnie Li, Esq.**

**Baker & McKenzie LLP**

**Suite 3401, China World Office 2**

**China World Trade Centre**

**1 Jianguomenwai Dajie**

**Beijing 100004**

**People's Republic of China**

**(86-10) 6535-3800**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ◻ <br> Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement is being filed by Baird Medical Investment Holdings Limited (the "Registrant") to register additional Class A ordinary shares issuable pursuant to its 2024 Equity Incentive Plan (the "2024 Plan") and consists of only those items required by General Instruction E to Form S-8. Pursuant to certain provisions of the 2024 Plan (referred to as the "evergreen provisions"), the number of ordinary shares that are available for award grant purposes under the 2024 Plan is automatically increased each year in accordance with a formula set forth in the 2024 Plan. Based on the above, the additional securities registered hereby consist of 1,229,381 Class A ordinary shares that were automatically added to the 2024 Plan, effective January 1, 2026, pursuant to the 2024 Plan's evergreen provisions.

In accordance with General Instruction E to Form S-8, the contents of the Registrant's Registration Statement on Form S-8, filed on January 10, 2025, are incorporated herein by reference, except as otherwise set forth herein.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and, accordingly, files periodic reports and other information with the Commission. The Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission, including the Registrant. The address for the Commission's website is "http://www.sec.gov." The following documents are incorporated by reference in this Registration Statement:

(a) The Registrant's [Annual Report on Form 20-F for the fiscal year ended December 31, 2024 filed with the Commission on May 15, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1982444/000141057825001328/bdmd-20241231x20f.htm);

(b) The Registrant's Current [Reports on Form 6-K furnished to the Commission on December 5, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1982444/000110465925118866/bdmd-20251205x6k.htm) and [February 10, 2026](https://www.sec.gov/Archives/edgar/data/1982444/000110465926012354/tm265365d1_6k.htm); and

(c) The description of the Registrant's ordinary shares incorporated by reference in its registration statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1982444/000110465924104955/tm2425225d2_8a12b.htm) (File No. 001-42300) filed with the Commission under Section 12(b) of the Exchange Act on October 1, 2024, including any amendments or reports filed for the purpose of updating such description.

Except to the extent such information is deemed furnished and not filed pursuant to securities laws and regulations, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act and, to the extent specifically designated therein, reports on Form 6-K furnished by the Registrant to the Commission, in each case, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered under this Registration Statement have been sold, or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing or furnishing of such documents.

Any statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

None.

**Item 6. Indemnification of Directors and Officers.**

Cayman Islands law does not limit the extent to which a company's articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. The Registrant's amended and restated memorandum and articles of association provide that the Registrant shall, subject to the limitations contained therein, indemnify each of its directors and officers (but not including its auditor) against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person's dishonesty, willful default or fraud, in or about the conduct of the Registrant's business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [5.1 \*](tm263761d1_ex5-1.htm) | [Opinion of Conyers Dill & Pearman](tm263761d1_ex5-1.htm) |
| [10.1](https://www.sec.gov/Archives/edgar/data/1982444/000110465925002524/tm251995d1_ex10-1.htm) | [Baird Medical Investment Holdings Limited 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-8 (Reg. No. 333-284206), initially filed with the SEC on January 10, 2025)](https://www.sec.gov/Archives/edgar/data/1982444/000110465925002524/tm251995d1_ex10-1.htm) |
| [23.1 \*](tm263761d1_ex23-1.htm) | [Consent of Kreit & Chiu CPA LLP](tm263761d1_ex23-1.htm) |
| [23.2 \*](tm263761d1_ex5-1.htm) | [Consent of Conyers Dill & Pearman (included as Exhibit 5.1)](tm263761d1_ex5-1.htm) |
| [23.3 \*](tm263761d1_ex23-3.htm) | [Consent of Marcum Asia CPAs LLP](tm263761d1_ex23-3.htm) |
| [24.1 \*](#a_001) | [Power of Attorney (included on signature page hereof)](#a_001) |
| [107\*](tm263761d1_ex-filingfees.htm) | [Filing Fee Table](tm263761d1_ex-filingfees.htm) |

---

\* Filed herewith.

**Item 9. Undertakings.**

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

*provided, however*, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b).

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. *Provided*, *however*, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Guangzhou, PRC, on March 10, 2026.

---

| | | |
|:---|:---|:---|
| **Baird Medical Investment Holdings Limited** | **Baird Medical Investment Holdings Limited** | **Baird Medical Investment Holdings Limited** |
| By: | /s/ Haimei Wu |  |
|  | Haimei Wu | |
|  | Director and Chief Executive Officer |  |
|  | *(principal executive officer)* |  |

---

**POWER OF ATTORNEY**

Each person whose signature appears below hereby appoints Haimei Wu his or her true and lawful attorney-in-fact with full power of substitution or re-substitution, for such person and in such person's name, place and stead, in any and all capacities, to sign on such person's behalf, individually and in each capacity stated below, any and all amendments, including post-effective amendments to this Registration Statement, and to sign any and all additional registration statements relating to the same offering of securities of the Registration Statement that are filed pursuant to Rule 462 of the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Haimei Wu | Director and Chief Executive Officer | March 10, 2026 |
| Name: Haimei Wu | *(Principal Executive Officer)* |  |
| /s/ Jie Li | Acting Chief Financial Officer | March 10, 2026 |
| Name: Jie Li | *(Principal Financial and Accounting Officer)* |  |
| /s/ Wei Hou | Director | March 10, 2026 |
| Name: Wei Hou |  |  |
| /s/ Quan Qiu | Director | March 10, 2026 |
| Name: Quan Qiu |  |  |
| /s/ Joseph Douglas Ragan III | Independent Director | March 10, 2026 |
| Name: Joseph Douglas Ragan III |  |  |
| /s/ Michael Mingzhao Xing | Independent Director | March 10, 2026 |
| Name: Michael Mingzhao Xing |  |  |
| /s/ Lijian Xu | Independent Director | March 10, 2026 |
| Name: Lijian Xu |  |  |
| /s/ Gabrielle Bilciu-Wolfson | Independent Director | March 10, 2026 |
| Name: Gabrielle Bilciu-Wolfson |  |  |

---

**SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES**

Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America of the Registrant, has signed this registration statement thereto in New York, NY on March 10, 2026.

---

| | |
|:---|:---|
| Puglisi & Associates<br> Authorized U.S. Representative | Puglisi & Associates<br> Authorized U.S. Representative |
| By: | /s/ Donald J. Puglisi |
| Name: | Donald J. Puglisi |
| Title: | Managing Director |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](tm263761d1_ex5-1img001.jpg) | **CONYERS DILL & PEARMAN**<br>29<sup>th</sup> Floor<br> One Exchange Square<br> 8 Connaught Place<br> Central<br> Hong Kong<br> T +852 2524 7106 \| F +852 2845 9268<br>**conyers.com** |

---

10 March 2026

Matter No.: 1014676 / 111652056

(852) 2842 9549 / (852) 2842 9403

<u>Angie.Chu@conyers.com</u>

<u>Beverly.Cheung@conyers.com</u>

**Baird Medical Investment Holdings Limited**

Cricket Square

Hutchins Drive

P.O. Box 2681

Grand Cayman

KY1-1111

Cayman Islands

Dear Sirs,

**Re: Baird Medical Investment Holdings Limited (the "Company")**

We have acted as special legal counsel in the Cayman Islands to the Company in connection with a registration statement on Form S-8 (the "**Registration Statement**", which term does not include any other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto) relating to the registration under the U.S. Securities Act of 1933, as amended, (the "**Securities Act**") of 1,229,381 ordinary shares of par value US$0.0001 each of the Company (the "**Shares**") issuable pursuant to the Company's 2024 Equity Incentive Plan (the "**Equity Incentive Plan**").

**1.** **DOCUMENTS REVIEWED** 

For the purposes of giving this opinion, we have examined copies of the following documents:

1.1 the
 Registration Statement; and

1.2 the
 Equity Incentive Plan.

We have also reviewed copies of:

1.3 the
 amended and restated memorandum and articles of association of the Company adopted on 1 October 2024
 (the "**M&As** ");

1.4 the unanimous written resolutions of the directors of the Company dated 26
September 2024 and the written resolutions of the then sole member of the Company dated 25 September 2024 (collectively, the **"2024 Resolutions"**);

1.5 the
unanimous written resolutions of the directors of the Company dated 9 March 2026 (together with
the 2024 Resolutions, the "**Resolutions**") ;

1.6 a
 Certificate of Good Standing issued by the Registrar of Companies in relation to the Company
 on 3 March 2026 (the "**Certificate Date** "); and

1.7 such
 other documents and made such enquiries as to questions of law as we have deemed necessary
 in order to render the opinion set forth below.

**2.** **ASSUMPTIONS** 

We have assumed:

2.1 the
 genuineness and authenticity of all signatures and the conformity to the originals of all
 copies (whether or not certified) examined by us and the authenticity and completeness of
 the originals from which such copies were taken;

2.2 that
 where a document has been examined by us in draft form, it will be or has been executed and/or
 filed in the form of that draft, and where a number of drafts of a document have been examined
 by us all changes thereto have been marked or otherwise drawn to our attention;

2.3 the
 accuracy and completeness of all factual representations made in the Registration Statement
 and the Equity Incentive Plan and other documents reviewed by us;

2.4 that
 the Resolutions were passed at one or more duly convened, constituted and quorate meetings
 or by unanimous written resolutions, remain in full force and effect and have not been rescinded
 or amended;

2.5 the "2024 Equity Incentive
Plan of the Company" as referred to in the M&As is the Equity Incentive Plan;

2.6 that
 there is no provision of the law of any jurisdiction, other than the Cayman Islands, which
 would have any implication in relation to the opinions expressed herein;

2.7 the
 validity and binding effect under the laws of the State of New York of the Registration Statement
 in accordance with its terms and that the Registration Statement will be duly filed with
 the U.S. Securities and Exchange Commission and have become effective prior to the issue
 by the Company of any Shares under the Equity Incentive Plan;

#### conyers.com \| 2
2.8 that
 there is no provision of any award agreement, incentive share option, non-qualified share
 option, restricted shares, restricted share units, performance award or other types of awards
 otherwise granted pursuant to the Equity Incentive Plan which would have any implication
 in relation to the opinions expressed herein;

2.9 the
 Company has not taken any action to appoint a restructuring officer;

2.10 that
 upon issue of the Shares, the Company will receive consideration for the full issue price
 thereof which shall be equal to at least the par value thereof;

2.11 that
 on the date of issuance of any of the Shares, the Company will have sufficient authorised
 but unissued Shares;

2.12 that
 on the date of issuing of any awards under the Equity Incentive Plan, the Company is able
 to pay its debts;

2.13 the
 issue of any Shares are made in accordance with the terms and conditions of the Equity Incentive
 Plan; and

2.14 the
 number of Shares which may be delivered pursuant to the Equity Incentive Plan are within
 the limit provided under the Equity Incentive Plan.

**3.** **QUALIFICATIONS** 

3.1 "Non-assessability"
 is not a legal concept under Cayman Islands law, but when we describe the Shares herein as
 being "non-assessable" we mean, subject to any contrary provision in any agreement
 between the Company and any one of its members holding any of the Shares (but only with respect
 to such member), that no further sums are payable with respect to the issue of such Shares
 and no member shall be bound by an alteration in the constitutional documents of the Company
 after the date upon which it became a member if and so far as the alteration requires such
 member to take or subscribe for additional Shares or in any way increases its liability to
 contribute to the share capital of, or otherwise pay money to, the Company.

3.2 We
 express no opinion with respect to the issuance of Shares pursuant to any provision of the
 Equity Incentive Plan that purports to obligate the Company to issue any Shares following
 the commencement of a winding up or liquidation.

3.3 We
 have made no investigation of and express no opinion in relation to the laws of any jurisdiction
 other than the Cayman Islands. This opinion is to be governed by and construed in accordance
 with the laws of the Cayman Islands and is limited to and is given on the basis of the current
 law and practice in the Cayman Islands. This opinion is issued solely for the purposes of
 the filing of the Registration Statement and is not to be relied upon in respect of any other
 matter.

#### conyers.com \| 3
**4.** **OPINION** 

On the basis of and subject to the foregoing, we are of the opinion that:

4.1 The
 Company is duly incorporated and existing under the law of the Cayman Islands and, based
 on the Certificate of Good Standing, is in good standing as at the Certificate Date. Pursuant
 to the Companies Act (the "**Act** "), a company is deemed to be in good standing
 if all fees and penalties under the Act have been paid and the Registrar of Companies has
 no knowledge that the Company is in default under the Act.

4.2 When
 issued and paid for as contemplated by the Equity Incentive Plan and registered in the register
 of members of the Company, the Shares will be validly issued, fully paid and non-assessable
 (which term when used herein means that no further sums are required to be paid by the holders
 thereof in connection with the issue thereof).

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not hereby admit that we are experts within the meaning of Section 11 of the Securities Act or that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission promulgated thereunder.

Yours faithfully,

/s/ Conyers Dill & Pearman

**Conyers Dill & Pearman**

#### conyers.com \| 4

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Baird Medical Investment Holdings Limited (the "Company") of our report dated May 15, 2025, which appears in the Company's Annual Report on Form 20-F for the year ended December 31, 2024.

/s/ Kreit & Chiu CPA LLP

Los Angeles, California

March 10, 2026

## Exhibit 23.3

**Exhibit 23.3**

![](tm263761d1_ex23-3img01.jpg)

**INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated June 20, 2024 relating to the financial statements appearing in the Annual Report on Form 20-F of Baird Medical Investment Holdings Limited for the year ended December 31, 2024.

/s/ Marcum Asia CPAs LLP

Guangzhou, China

March 9, 2026

GUANGZHOU OFFICE • Ste.1712 • CTF Finance Center • 6 Pearl River East Rd. • Pearl River New Town • Tianhe Dist. • Guangzhou • 510623

Phone 646.442.4845 • Fax 646.349.5200 • www.marcumasia.com

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Baird Medical Investment Holdings Ltd**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Ordinary Shares, par value $0.0001 per share | 457(a) | 1229381 | $3.18 | $3909431.58 | 0.0001381 | $539.89 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $3909431.58  |  | $539.89  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $539.89  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Represents ordinary shares which are issuable under the 2024 Equity Incentive Plan of the Registrant. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement is deemed to cover an indeterminate number of ordinary shares which may be offered and issued to prevent dilution resulting from share splits, share dividends or similar transactions as provided in the 2024 Equity Incentive Plan. Represents ordinary shares to be issued pursuant to the evergreen provision in the 2024 Equity Incentive Plan. The proposed maximum offering price per share, which is estimated solely for the purposes of calculating the registration fee under Rule 457(h) and Rule 457(c) under the Securities Act, is based on US$3.180 per share, the average of the high and low prices for the Registrant's ordinary shares as quoted on the Nasdaq Capital Market on March 6, 2026. Any ordinary share covered by an award granted under the 2024 Equity Incentive Plan (or portion of an award) that is forfeited, cancelled or otherwise expired for any reason without having been exercised shall be deemed not to have been issued for purposes of determining the maximum aggregate number of ordinary shares which may be issued under the 2024 Equity Incentive Plan.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---